• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?

作者信息

Nasiripour Somayyeh, Zamani Farhad, Farasatinasab Maryam

机构信息

Department of Clinical Pharmacy, School of Pharmacy-International Campus, Iran University of Medical Sciences, Tehran, Iran.

Department of Internal Medicine, Gastrointestinal & Liver Disease Research Center (GILDRC), Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.

出版信息

J Clin Pharmacol. 2020 Jul;60(7):828-829. doi: 10.1002/jcph.1645. Epub 2020 May 23.

DOI:10.1002/jcph.1645
PMID:32445400
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7283693/
Abstract
摘要

相似文献

1
Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?秋水仙碱作为一种古老的抗炎药物，对新冠病毒肺炎是否有效？
J Clin Pharmacol. 2020 Jul;60(7):828-829. doi: 10.1002/jcph.1645. Epub 2020 May 23.
2
Treating COVID-19 with colchicine in community healthcare setting.在社区医疗环境中使用秋水仙碱治疗新冠病毒病
Clin Immunol. 2020 Aug;217:108490. doi: 10.1016/j.clim.2020.108490. Epub 2020 May 31.
3
Pros and cons of corticosteroid therapy for COVID-19 patients.COVID-19 患者使用皮质类固醇治疗的利弊。
Respir Physiol Neurobiol. 2020 Sep;280:103492. doi: 10.1016/j.resp.2020.103492. Epub 2020 Jul 10.
4
Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?新型冠状病毒2感染的急性炎症与发病机制：大麻二酚能否作为一种潜在的抗炎治疗方法？
Cytokine Growth Factor Rev. 2020 Jun;53:63-65. doi: 10.1016/j.cytogfr.2020.05.008. Epub 2020 May 20.
5
The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的多重效应提示其对新冠病毒疾病（COVID-19）患者可能有益。
Can J Cardiol. 2020 Oct;36(10):1691.e3. doi: 10.1016/j.cjca.2020.07.230. Epub 2020 Jul 24.
6
Successful use of methylprednisolone for treating severe COVID-19.甲基泼尼松龙成功用于治疗重症新型冠状病毒肺炎。
J Allergy Clin Immunol. 2020 Aug;146(2):325-327. doi: 10.1016/j.jaci.2020.05.021. Epub 2020 May 29.
7
Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?秋水仙碱作为COVID-19的一种强效抗炎治疗方法：我们能让老狗学新把戏吗？
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):255. doi: 10.1093/ehjcvp/pvaa033.
8
The efficacy of colchicine in the management of coronavirus disease 2019: A protocol for systematic review and meta-analysis.秋水仙碱治疗2019冠状病毒病的疗效：一项系统评价和荟萃分析方案
Medicine (Baltimore). 2020 Sep 4;99(36):e21911. doi: 10.1097/MD.0000000000021911.
9
Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality.COVID-19 大流行期间心包疾病的抗炎治疗：安全性和潜力。
J Cardiovasc Med (Hagerstown). 2020 Sep;21(9):625-629. doi: 10.2459/JCM.0000000000001059.
10
Should we unstress SARS-CoV-2 infected cells?我们是否应该减轻感染了新冠病毒的细胞的应激反应？
Cytokine Growth Factor Rev. 2020 Aug;54:3-5. doi: 10.1016/j.cytogfr.2020.06.011. Epub 2020 Jun 11.

引用本文的文献

1
COVID-19 management in patients with comorbid conditions.合并症患者的 COVID-19 管理。
World J Virol. 2025 Jun 25;14(2):102674. doi: 10.5501/wjv.v14.i2.102674.
2
Insight into the emerging and common experimental in-vivo models of Alzheimer's disease.对阿尔茨海默病新兴且常见的体内实验模型的洞察。
Lab Anim Res. 2023 Dec 11;39(1):33. doi: 10.1186/s42826-023-00184-1.
3
The DNA glycosylase NEIL2 is protective during SARS-CoV-2 infection.DNA 糖苷酶 NEIL2 在 SARS-CoV-2 感染过程中具有保护作用。
Nat Commun. 2023 Dec 9;14(1):8169. doi: 10.1038/s41467-023-43938-0.
4
The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial.秋水仙碱对住院 COVID-19 患者的影响：一项随机、双盲、安慰剂对照的临床试验。
J Investig Med. 2023 Feb;71(2):124-131. doi: 10.1177/10815589221141815. Epub 2023 Jan 16.
5
Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review.2019冠状病毒病疫苗与治疗方法的当前进展及未来前景：一篇叙述性综述
Ther Adv Vaccines Immunother. 2022 May 30;10:25151355221097559. doi: 10.1177/25151355221097559. eCollection 2022.
6
Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis.秋水仙碱治疗新冠病毒肺炎患者的疗效：一项系统评价与荟萃分析
J Clin Med. 2022 May 6;11(9):2615. doi: 10.3390/jcm11092615.
7
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.治疗 COVID-19 的小分子临床试验的种族差异：最新全面综述。
Drug Dev Res. 2022 Feb;83(1):16-54. doi: 10.1002/ddr.21895. Epub 2021 Nov 11.
8
Colchicine Blocks Tubulin Heterodimer Recycling by Tubulin Cofactors TBCA, TBCB, and TBCE.秋水仙碱通过微管蛋白辅助因子TBCA、TBCB和TBCE阻断微管蛋白异二聚体的循环利用。
Front Cell Dev Biol. 2021 Apr 22;9:656273. doi: 10.3389/fcell.2021.656273. eCollection 2021.
9
Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review.潜在的 COVID-19 治疗药物和疫苗：基于证据的综述。
J Clin Pharmacol. 2021 Apr;61(4):429-460. doi: 10.1002/jcph.1822. Epub 2021 Mar 5.
10
Repurposing medications.药物再利用。
Ocul Surf. 2021 Jan;19:336-340. doi: 10.1016/j.jtos.2020.11.012. Epub 2020 Nov 26.

本文引用的文献

1
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
2
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
3
Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug design.解析II期临床试验血管破坏剂BNC105的分子机制，为药物设计提供了思路。
Biochem Biophys Res Commun. 2020 Feb 18. doi: 10.1016/j.bbrc.2019.12.083.
4
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
5
Update on colchicine, 2017.2017 年秋水仙碱研究进展。
Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i4-i11. doi: 10.1093/rheumatology/kex453.
6
Effects of colchicine on pericardial diseases: a review of the literature and current evidence.秋水仙碱对心包疾病的影响：文献综述与当前证据
J Community Hosp Intern Med Perspect. 2016 Jul 6;6(3):31957. doi: 10.3402/jchimp.v6.31957. eCollection 2016.
7
Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome.秋水仙碱可急性抑制急性冠状动脉综合征患者局部心脏炎症细胞因子的产生。
J Am Heart Assoc. 2015 Aug 24;4(8):e002128. doi: 10.1161/JAHA.115.002128.
8
Mechanism of action of colchicine in the treatment of gout.秋水仙碱治疗痛风的作用机制。
Clin Ther. 2014 Oct 1;36(10):1465-79. doi: 10.1016/j.clinthera.2014.07.017. Epub 2014 Aug 21.
9
Current concepts in the diagnosis and management of cytokine release syndrome.细胞因子释放综合征的诊断和治疗的当前概念。
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
10
Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine.秋水仙碱在痛风性关节炎小鼠模型中抑制中性粒细胞超氧化物生成：低剂量秋水仙碱应用的理论依据。
Br J Pharmacol. 2008 Mar;153(6):1288-95. doi: 10.1038/bjp.2008.20. Epub 2008 Feb 11.